Month: December 2022

Posted on

Red Stamp Package Pilot Project

Postal customers can now get or pick up Red Stamp items at the Department of Postal Services more easily and quickly with the implementation of the Red Stamp Package Pilot Project. With the implementation of the project, customers can make tax payments online for their red stamp parcels.

 

The Red Stamp Package Pilot Project is implemented through the joint efforts of the Department of Postal Services with the Royal Customs and Excise Department, Ministry of Finance and Economy and related government agencies. It allows postal customers to give permission to the Department of Postal Services to open their mail in the presence of Royal Customs and Excise officers for inspection purposes.

 

Applicants or customers wishing to use the service must first ensure the whereabouts of their goods by using the ‘Brutrack’ app or the Department of Postal Service’s website and have the ‘QueUp’ app to fill in the required information. If goods are subject to tax, customers can make payments online through the application or Bank Islam Brunei Darussalam, BIBD’s website. The taxes imposed is according to the price and shipment cost of the goods.

 

 

Source: Radio Television Brunei

Posted on

Ke Temburong Bisai’ Programme

To enliven Temburong District in conjunction with the December school holidays, the District’s Mukim and Village Consultative Councils in collaboration with the Temburong District Office once again held the ‘Ke Temburong Bisai’ Programme. The four-day programme started yesterday until 1st January 2023, at the Civic Centre Complex, Bangar Town, Temburong.

 

The programme provides opportunities for One Village One Product, 1K1P and other village product entrepreneurs to generate income and promote their products. The programmes of the ‘Ke Temburong Bisai’ programme includes the Village Entrepreneurship Sales activity with the participation of sixty-six 1K1P entrepreneurs and small and medium entrepreneurs from within and outside the district. The programme is held from 2 in the afternoon to 8 in the evening and on 31st December, 2022 and 1st January, 2023, it will  held from 8 in the morning to 8 in the evening.

 

 

Source: Radio Television Brunei

Posted on

Philippines’ Marcos to raise South China Sea dispute during Beijing state visit

Philippine leader Ferdinand Marcos Jr. will raise the South China Sea dispute and assert Manila’s sovereignty over its territorial waters when he meets Chinese President Xi Jinping next week during his first presidential visit to Beijing, officials said Thursday.

Marcos is embarking on the Jan 3-5 state visit weeks after Manila accused Chinese boats of  “swarming” in South China Sea waters within the Philippines’ exclusive economic zone.

He will bring up issues “affecting bilateral relations, among them the issue [of the] WPS,” said Neil Imperial, the Philippine assistant foreign secretary for Asian and Pacific Affairs. “WPS” refers to the West Philippine Sea, Manila’s name for territories and waters it claims in the South China Sea.

“The president wants a peaceful and stable situation in the WPS and will continue to uphold our country’s sovereignty and sovereign rights during his meetings with Chinese leaders,” Imperial told reporters in an online press briefing.

The foreign department, however, will not “second guess what the president will say to [his] counterpart,” he said.

In addition, the foreign ministries of both governments are set to sign an agreement “establishing direct communication” to avoid “miscalculation and miscommunication” in the contested sea region, Imperial said. Details of the proposed pact were not immediately available.

The Philippine foreign office said earlier that it had sent 193 diplomatic protests to China this year alone – 65 of those since Marcos assumed the presidency in June.

China claims nearly all of the South China Sea on historical grounds, including waters within the exclusive economic zones of Brunei, Malaysia, the Philippines, Vietnam, and Taiwan. Beijing also claims historic rights to areas of the waterway that overlap Indonesia’s exclusive economic zone as well.

“The president has said that the maritime issues do not define the totality of our bilateral relations with China, but nevertheless, he acknowledges the importance of this issue to our interest and that of the Filipino people,” Imperial said.

For part of the bilateral meeting, at least, both leaders will likely discuss energy cooperation, especially in oil and gas.

The foreign department also said that it expected major Chinese investment pledges during the trip, particularly in the areas of agriculture, renewable energy and nickel processing – China supplies about 70 percent of nickel ore and concentrates to Manila.

Presidents Marcos and Xi have met once before, in Bangkok, on the sidelines of the APEC summit in November.

“With both leaders receiving a fresh mandate in recent elections, there is an expectation that the state visit will set the tone of bilateral ties between the two countries in the next five to six years,” Imperial said.

In September, Marcos met with President Joe Biden in New York on the sidelines of the United Nations General Assembly meeting.

During their meeting, Biden “reaffirmed the United States’ ironclad commitment to the defense of the Philippines.”

Concerns over COVID-19

Meanwhile, Marcos’s appointments office said that the Philippine president’s trip was shortened to three days from the originally scheduled four days over concerns about the surge of a newer, more virulent COVID-19 variant. The Chinese government has assured the Philippine side that all safety protocols and restrictions will be followed, Philippine officials said.

Members of the official delegation who fall ill during the trip would be quarantined and isolated until they recover and are fit to fly home. Marcos as well as some members of his staff had earlier this year been infected, with the president having to be isolated shortly after he took office.

The government has had to scrap planned meetings by Marcos with the significant Filipino expatriate community in Beijing, while those traveling with the president would have to undergo quarantine upon arrival at a special facility.

Earlier on Thursday, Health Undersecretary Maria Rosario Vergeire said the country didn’t see a need to shut down its borders or impose tighter restrictions for Chinese travelers despite the spread of the new COVID-19 variant in China.

“We can’t just have closures, then open it, then close it again,” she said, adding she believed that health protocols already in place were sufficient.

“We are moving forward.”

 

Radio Free Asia –Copyright © 1998-2016, RFA. Used with the permission of Radio Free Asia, 2025 M St. NW, Suite 300, Washington DC 20036

 

Posted on

Chinese Jet Came Within 10 Feet of US Military Aircraft, Says US Military

A Chinese military plane came within 3 meters of a U.S. Air Force aircraft in the contested South China Sea last week and forced it to take evasive maneuvers to avoid a collision in international airspace, the U.S. military said Thursday.

The close encounter followed what the United States has called a recent trend of increasingly dangerous behavior by Chinese military aircraft.

The incident, which involved a Chinese Navy J-11 fighter jet and a U.S. air force RC-135 aircraft, took place on December 21, the U.S. military said in a statement.

“We expect all countries in the Indo-Pacific region to use international airspace safely and in accordance with international law,” it added.

A U.S. military spokesperson said the Chinese jet came within 10 feet of the plane’s wing, but 20 feet from its nose, which caused the U.S. aircraft to take evasive maneuvers.

The U.S. has raised the issue with the Chinese government, a separate U.S. official said.

The Chinese embassy in Washington did not immediately respond to a request for comment.

In the past, China has said the U.S. sending ships and aircraft into the South China Sea is not good for peace.

U.S. military planes and ships routinely carry out surveillance operations and travel through the region.


China claims vast swathes of the South China Sea that overlap with the exclusive economic zones of Vietnam, Malaysia, Brunei, Indonesia and the Philippines.

Trillions of dollars in trade flow every year through the waterway, which also contains rich fishing grounds and gas fields.

In a meeting with his Chinese counterpart in November, U.S. Defense Secretary Lloyd Austin raised the need to improve crisis communications, and also noted what he called dangerous behavior by Chinese military planes.

Despite tensions between the U.S. and China, U.S. military officials have long sought to maintain open lines of communication with their Chinese counterparts to mitigate the risk of potential flare-ups or deal with any accidents.

Other countries report harassment

Australia’s defense department said in June that a Chinese fighter aircraft dangerously intercepted an Australian military surveillance plane in the South China Sea region in May.

Australia said the Chinese jet flew close in front of the RAAF aircraft and released a “bundle of chaff” containing small pieces of aluminum that were ingested into the Australian aircraft’s engine.

In June, Canada’s military accused Chinese warplanes of harassing its patrol aircraft as they monitored North Korea sanction evasions, sometimes forcing Canadian planes to divert from their flight paths.

Friction between China and U.S.

Relations between China and the U.S. have been tense, with friction between the world’s two largest economies over everything from Taiwan and China’s human rights record to its military activity in the South China Sea.

U.S. House Speaker Nancy Pelosi’s trip to Taiwan in August infuriated China, which saw it as a U.S. attempt to interfere in its internal affairs. China subsequently launched military drills near the island.

The U.S. has no formal diplomatic relations with Taiwan but is bound by law to provide the island with the means to defend itself.

Source: Voice of America

 

Posted on

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

SHANGHAI, China, Dec. 29, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online publication in New England Journal (NEJM) of the Phase 3 trial (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of symptomatic patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death. It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

The study, led by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, is the first “head-to-head” phase III clinical study of small molecule oral anti-SARS-CoV drug in Chinese COVID-19 patients during the Omicron outbreak. The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.

The Article was co-authored by Professor Ren ZHAO of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Professor Yuan GAO of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Professor Guang NING, Professor Yiping XU and Professor Qing XIE of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine as co-corresponding authors, Zhujun CAO and Weiyi GAO of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Hong BAO of Pudong Hospital, Fudan University, Haiyan FENG of Shanghai Public Health Clinical Center and Shuya MEI of Renji Hospital, Shanghai Jiao Tong University School of Medicine as co-first authors.

“Thanks to the support of the patients and study team, we have achieved great success in this clinical study and were recognized by the prestigious New England Journal of Medicine,” said Professor Ren ZHAO. “Our study not only provided valuable information and experience for the development and clinical application of two major anti-SARS-CoV-2 small molecule drug routes, the RdRp inhibitor and the 3CL protease inhibitor, but also showed that our self-developed anti-SARS-CoV-2 oral drugs in China have similar efficacy and safety to PAXLOVID. We hope that our study results can assist in our nation’s efforts to combat the epidemic.”

“Presently, the treatment and prevention of COVID-19 is still full of challenges, particularly in the treatment of patients who are at high risk for progression to severe COVID-19,” said Jianjun ZOU, Global Research and Development President at Junshi Biosciences. “The current treatment needs to be made more widely applicable and accessible to a larger population. The publication of this study in the NEJM demonstrates that the international academic community has recognized the clinical development of drugs led by Chinese investigators and pharmaceutical companies in terms of trial design, quality, and results. We are continuing to invest in the clinical development of VV116 for use in other populations, with the goal of providing better and safer treatment options for COVID-19 patients in China and around the world with this exciting new therapy!”

At present, the COVID-19 pandemic continues to spread rapidly worldwide, and the transmission and escape ability of the virus continues to increase with variation. Oral antiviral drugs are considered to be one of the essential response against the pandemic because of their advantages of convenient administration, high resistance barrier, and less transportation and storage restrictions, which help to alleviate the medical burden. However, there are still a number of factors that lead to limited use of the drugs (such as the interaction between drug and drug, accessibility, etc.), so more effective and safe therapeutic drugs need to be developed.

VV116 is an oral nucleoside antiviral drug independently developed in China that inhibits the replication of SARS-CoV-2. Preclinical studies have shown that VV116 had significant antiviral effects in both original strain and known mutant strains, and exhibited satisfactory safety, tolerability, and pharmacokinetic properties in phase I clinical studies1. A preliminary small-scale study confirmed that patients, who were treated with VV116 within 5 days since they were tested positive after the first SARS-CoV-2 detection, had a shorter time to nucleic acid reversion compared to conventional therapy2.

This publication is related to a multicenter, single-blind (observers remain blinded), randomized, controlled Phase III clinical trial (NCT05341609) conducted jointly at seven COVID-19 designated hospitals in Shanghai from April 4 to May 2, 20223, which included a total of 822 adult patients with mild to moderate COVID-19 diagnosed at high risk of progression and assigned to the VV116 group and PAXLOVID group on a proportion of 1:1. Finally, a total of 771 patients (Full Analysis Set, FAS) were treated with VV116 (n = 384) or PAXLOVID (n = 387).

Among them, the median age of FAS patients was 53 (range: 18-94), 50.2% of them were female, 92.1% of them had mild COVID-19, 75.7% of them were fully vaccinated or boosted, and 77.3% of them received VV116 or PAXLOVID therapy within 5 days after symptom onset. The most common high-risk factors in patients were: age ≥ 60 years (37.7%), cardiovascular disease including hypertension (35.1%), obesity or overweight BMI ≥ 25 (32.9%), current smoking (12.5%), and diabetes (10.1%).

The primary end point of the study was the time from randomization to sustained clinical recovery, with a lower boundary of the two-sided 95% confidence interval (CI) for the hazard ratio (HR) > 0.8 defined as noninferiority. Secondary efficacy end points included the proportion of patients who progressed to severe or critical COVID-19 or death from any cause by Day 28, the change in COVID-19 related symptom score and the score on the WHO Clinical Progression Scale, time to sustained resolution of all target symptoms, and to a first negative SARS-CoV-2 test. Safety endpoints included adverse events (AEs) and serious adverse events (SAEs).

According to the final analysis (as of August 18, 2022), VV116 and PAXLOVID achieved noninferiority in the “time to sustained clinical recovery” in the FAS population (HR = 1.17, 95% CI: 1.02~1.36), and the median time to sustained clinical recovery was shorter in the VV116 group than that in the PAXLOVID group (4 days vs. 5 days).

For VV116 group and PAXLOVID group, they showed similar results in respect of “time to sustained resolution of all target symptoms” and “time to a first negative SARS-CoV-2 test”, with a median time of 7 days. At each preset time point (Days 5, 7, 10, 14, and 28), the proportion of patients with clinical recovery was larger in the VV116 group than that in the PAXLOVID group. No patients in either group hase progression to severe/critical COVID-19 or had died.

In addition, about 3/4 of the patients in this study had vaccinated against SARS-CoV-2, and such patients have been excluded from most trials, and subgroup analysis showed that there was no statistically significant difference in the treatment results between VV116 and PAXLOVID in the vaccinated or unvaccinated population.

VV116 showed fewer safety concern than PAXLOVID. The incidence of AEs in VV116 group was lower than that in the PAXLOVID group (all-grade AEs: 67.4% vs. 77.3%, Grade 3 or 4 AE: 2.6% vs. 5.7%).

It should be noted that PAXLOVID has multiple drug-drug interactions, while VV116 does not inhibit or induce major drug-metabolism enzymes, or inhibit major drug transporters, and is therefore less likely to interact with the drugs for combination therapy.

About VV116 (JT001)
VV116 is an oral nucleoside analog drug that can inhibit the replication of SARS-CoV-2. During preclinical pharmacodynamic studies, VV116 exerted an antiviral effect on the original strain of the novel coronavirus and its known variants in vitro; in the mice model, a low dose of VV116 reduced the virus titers below the detection limit, significantly lowered the chances of lung injury and displayed a strong antiviral effect. Preclinical pharmacokinetics and other research results also show that VV116 has high oral bioavailability. Following oral administration and absorption, VV116 is rapidly metabolized into parent nucleoside and widely distributed throughout the body.

VV116 was jointly developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; the Wuhan Institute of Virology, Chinese Academy of Sciences; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences; Central Asian Center of Drug Discovery and Development Chinese Academy of Sciences / China-Uzbekistan Medicine Technical Park (the Joint Laboratory of the Ministry of Science and Technology under the “The Belt and Road Initiative”); Lingang Laboratory; Vigonvita Life Sciences Co., Ltd. (“Vigonvita”); and Junshi Biosciences. Junshi Biosciences and Vigonvita are responsible for the clinical development and industrialization of VV116 worldwide. The areas of cooperation is global aside from five Central Asian countries, Russia, North Africa and the Middle East.

Junshi Biosciences and Vigonvita have completed three Phase I studies with healthy Chinese subjects, and one Phase III study in the patients with mild-to moderate COVID-19 at high risk to progression to severe COVID-19 in China (NCT05341609). Research results have been published in Acta Pharmacologica Sinica, and NEJM respectively.

In 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

1 Qian, Hj., et al. Acta Pharmacol Sin (2022).
2 Shen Y, et al. Emerg Microbes Infect 2022;11:1518-23.
3 The seven hospitals participating in the study were: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine; Pudong Hospital, Fudan University; Shanghai Public Health Clinical Centre; Shuguang Hospital, Shanghai University of Traditional Chinese Medicine; Huashan Hospital, Fudan University; and Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine.

GlobeNewswire Distribution ID 8721274

Posted on

UI GreenMetric 2022, Luiss among the top 20 most sustainable universities

UI GreenMetric 2022: Luiss among the top 20 most sustainable universities

Rome – Luiss continues to climb the UI GreenMetric 2022 ranking of the world’s most sustainable universities, taking 19th place globally among the 1,050 participating universities and 2nd place in Italy.

ROME, Dec. 28, 2022 (GLOBE NEWSWIRE) — Luiss continues to climb the UI GreenMetric 2022 ranking of the world’s most sustainable universities, taking 19th place globally among the 1,050 participating universities and 2nd place in Italy.

Since its first entry in 2018, Luiss has climbed more than 200 positions, starting at 229th. The entire Luiss community’s constant commitment to sustainability has led to a continuous increase in overall score, now 8,875. Also, in the category “Energy and Climate Change” in particular, Luiss ranked among the top universities worldwide, and first in Italy.

Luiss climbed the international rankings of Higher Education: according to the prestigious QS World University ranking by Subject, the University named after Guido Carli is 1st in Italy and 22nd in the world for Political and International Studies and in the Top 100 for the Social Sciences and Management area.

Luiss University is at 53rd place in the top 100 of the Financial Times’ 2022 Masters in Management ranking, with a leap of 23 places, making it the fastest rising in 2022 and putting it among the top universities in the world. There are many assets at the base of this result; one of the most relevant is the career progress of its graduates. The jump is due to improved performance in various categories, in particular average salary, salary increase, and career progress, which have helped Luiss achieve its highest overall rank since 2017.

The Luiss mission is to educate enquirers: curious, resilient, and open-minded professionals in the areas of economics, law, management, and political sciences that are rigorous and reliable to frame and solve issues. Luiss enquirers think like scientists while acting as business leaders, lawyers, managers, policymakers or entrepreneurs. They are deeply engaged in society because they combine their attitude with other people’s resources to meet shared objectives.

For more information:

LaPresse SpA Communication and Press Office Director
Barbara Sanicola – barbara.sanicola@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/18750bbd-7284-454a-a66a-29920fe962bb

GlobeNewswire Distribution ID 8720862

Posted on

AFF Mitsubishi Electric Cup

The AMEC 2022 campaign for Group A will resume tomorrow afternoon, 29th December with another two matches.

 

At 5 in the afternoon local time, the Brunei Darussalam squad will go up against Cambodia at Morodok Techo National Stadium, Cambodia. Meanwhile, Indonesia meets Thailand at Gelora Bung Karno Stadium, Indonesia at 4:30 in the afternoon.

 

 

Source: Radio Television Brunei

Posted on

Maintenance Work

Maintenance work for cameras mounted at the Sultan Haji Omar ‘Ali Saifuddien Bridge’s gantry are currently ongoing.

 

According to the Public Works Department, Ministry of Development, the maintenance work began yesterday morning until works are completed. In this regard, road users are advised to use the road detour provided and to exercise caution when using the bridge.

 

 

Source: Radio Television Brunei

 

Posted on

Unique Traditional Culture

For those wishing to experience the unique value of traditional culture and village life, Tutong District is offering such an experience for local or foreign tourists.

 

Located at Kampung Tanjong Maya, Lamin Warisan is one of the places famous for its uniqueness of providing the public with the chance to experience the way of life of villagers in the past. The Warisan Nature Trail package is one of the popular packages introduced to attract more local tourists. Through the package, visitors can experience the beauty of nature while getting to know several types of plants and herbs found in the area.

 

Not only does it give visitors a new experience, such a package is also able to further expand the tourism industry in the country.

 

 

Source: Radio Television Brunei

Posted on

Ambulong-Based Products

 

If Tutong District provides eco-tourism attractions, Temburong District has ambulong-based products that are very well known among the public. Let’s took a closer look at the uniqueness of the Ambulong Biscuits.

 

Dayang Normah binti Ismail, a member of the Women’s Bureau, Batu Apoi Village Consultative Council in Temburong District for the past 10 years have been active in producing Ambulong-based biscuit products. During the early stage, Dayang Normah repeatedly tried to make different types of Ambulong-based biscuits until she succeeded in producing 10 different flavours of ambulong biscuits.

 

To add variety to her biscuit products, Dayang Normah with the help of her children tried to add various flavours. Due to its unique taste, the biscuits are made to order as snacks, but the MPK also receives orders for large quantities as gifts at events such as weddings.

 

Currently, Dayang Normah’s ambulong biscuits are only available in Temburong District and Brunei Muara District. She plans to further expand the promotion of the ambulong biscuit products throughout the country.

 

 

Source: Radio Television Brunei

 

Posted on

Bonus as Motivation to Improve Work Quality

The moment that all Civil Servants look forward to as they receive their annual bonuses from the Government of His Majesty the Sultan and Yang Di-Pertuan of Brunei Darussalam. The bonus payment will certainly inspire the civil servants’ enthusiasm, dedication and commitment to work more diligently, sincerely, efficiently and brilliantly for the religion, nation and country.

 

The bonus payment is not only a sign of appreciation but also a motivation in improving the quality of work after their devoted service and working tirelessly for 12 months. With the bonus, not only can it alleviate the burden, but civil servants are able to get their own necessities. However, they are reminded to practise prudent spending.

 

 

Source: Radio Television Brunei

 

Posted on

Signing Of Scholarship Scheme Awards

 

The two students that received the Brunei Darussalam – Republic of Singapore Youth Education Scholarship Scheme Awards are determined to make full use of the opportunity to achieve academic excellence and be able to socialise with other international students. The award can certainly be a catalyst for them to achieve greater success, especially for the country. The two students will attend secondary level studies in the Republic of Singapore starting in January 2023. Yesterday morning, the Ministry of Education through the Department of Scholarship Management held the Scholarship Scheme Awards and Signing Ceremony for the 2023/2024 academic session.

 

Present was Yang Berhormat Datin Seri Setia Doctor Dayang Hajah Romaizah binti Haji Mohd. Salleh, Minister of Education. Signing on behalf of the Government of His Majesty the Sultan and Yang Di-Pertuan of Brunei Darussalam was Awang Julaihi bin Mohamad/Mohamat, Special Duties Officer at the Ministry of Education, while His Excellency Mr. Heng Aik Yeow, Republic of Singapore’s High Commissioner to Brunei Darussalam signed on behalf of the Republic of Singapore. The recipients were joined by two guarantors.

 

 

Source: Radio Television Brunei

 

Proudly powered by WordPress